Abstract:Background: Autism Spectrum Disorders (ASD) is a syndrome with a number of etiologies and different mechanisms that lead to abnormal development. The identification of autism biomarkers in patients with different degrees of clinical presentation (i.e., mild, moderate and severe) will give greater insight into the pathogenesis of this disease and will enable effective early diagnostic strategies and treatments for this disorder.
“…This suggests that individuals with ASDs may have a decreased ability to eliminate heavy metals from the body due to a genetic etiology (Kern et al, 2007). Furthermore, individuals with ASDs have impairments in detoxification and have lower levels of antioxidants, such as glutathione-s-transferase and vitamin E (Alabdali et al, 2014). This may cause these individuals to be more susceptible to the accumulation of toxic metals such as mercury and lead.…”
The prevalence of autism spectrum disorders (ASDs) has been on the rise over recent years. The presence of diverse subsets of candidate genes in each individual with an ASD and the vast variability of phenotypical differences suggest that the interference of an exogenous environmental component may greatly contribute to the development of ASDs. The lipid mediator prostaglandin E2 (PGE2 ) is released from phospholipids of cell membranes, and is important in brain development and function; PGE2 is involved in differentiation, synaptic plasticity and calcium regulation. The previous review already described extrinsic factors, including deficient dietary supplementation, and exposure to oxidative stress, infections and inflammation that can disrupt signaling of the PGE2 pathway and contribute to ASDs. In this review, the structure and establishment of two key protective barriers for the brain during early development are described: the blood-brain barrier; and the placental barrier. Then, the first comprehensive summary of other environmental factors, such as exposure to chemicals in air pollution, pesticides and consumer products, which can also disturb PGE2 signaling and increase the risk for developing ASDs is provided. Also, how these exogenous agents are capable of crossing the protective barriers of the brain during critical developmental periods when barrier components are still being formed is described. This review underlines the importance of avoiding or limiting exposure to these factors during vulnerable periods in development.
“…This suggests that individuals with ASDs may have a decreased ability to eliminate heavy metals from the body due to a genetic etiology (Kern et al, 2007). Furthermore, individuals with ASDs have impairments in detoxification and have lower levels of antioxidants, such as glutathione-s-transferase and vitamin E (Alabdali et al, 2014). This may cause these individuals to be more susceptible to the accumulation of toxic metals such as mercury and lead.…”
The prevalence of autism spectrum disorders (ASDs) has been on the rise over recent years. The presence of diverse subsets of candidate genes in each individual with an ASD and the vast variability of phenotypical differences suggest that the interference of an exogenous environmental component may greatly contribute to the development of ASDs. The lipid mediator prostaglandin E2 (PGE2 ) is released from phospholipids of cell membranes, and is important in brain development and function; PGE2 is involved in differentiation, synaptic plasticity and calcium regulation. The previous review already described extrinsic factors, including deficient dietary supplementation, and exposure to oxidative stress, infections and inflammation that can disrupt signaling of the PGE2 pathway and contribute to ASDs. In this review, the structure and establishment of two key protective barriers for the brain during early development are described: the blood-brain barrier; and the placental barrier. Then, the first comprehensive summary of other environmental factors, such as exposure to chemicals in air pollution, pesticides and consumer products, which can also disturb PGE2 signaling and increase the risk for developing ASDs is provided. Also, how these exogenous agents are capable of crossing the protective barriers of the brain during critical developmental periods when barrier components are still being formed is described. This review underlines the importance of avoiding or limiting exposure to these factors during vulnerable periods in development.
“…In considering the results observed in this study from a mechanistic point of view for ASD etiology, it was hypothesized that persons with oxidative stress and transsulfuration abnormalities would be a greater risk of developing an ASD following environmental toxicant exposures (Alabdali, Al‐Ayadhi, & El‐Ansary, ). Specifically, it was suggested that limited thiol availability, abnormal sulfation chemistry, and decreased glutathione reserve capacity in children would result in such persons having greater accumulation of environmental toxicants in the brain leading to neuronal damage, and, ultimately, an ASD diagnosis (Kern et al, ).…”
Autism spectrum disorder (ASD) is a neurodevelopmental disorder in which evidence reveals oxidative stress and transsulfuration pathway abnormalities. Down syndrome (DS) is a genetic disorder characterized by similar oxidative stress and transsulfuration pathway abnormalities. This hypothesis-testing longitudinal cohort study determined whether transsulfuration abnormalities and oxidative stress are important susceptibility factors in ASD etiology by evaluating the rate of ASD diagnoses in DS as compared to the general population. The Independent Healthcare Research Database was analyzed for healthcare records prospectively generated in Florida Medicaid. A cohort of 101,736 persons (born : 1990-1999) with ≥10 outpatient office visits and continuously followed for 120 months after birth was examined.There were 942 children in the DS cohort (ICD-9 code: 758.0) and 100,749 children in the undiagnosed cohort (no DS diagnosis). ASD diagnoses were defined as autistic disorder (ICD-9 code: 299.00) or Asperger's disorder/pervasive developmental disorder-not otherwise specified (ICD-9 code: 299.80). ASDs were diagnosed in 5.31% of the DS cohort and 1.34% of the undiagnosed cohort. The risk ratio of being diagnosed with an ASD in the DS cohort as compared to the undiagnosed cohort was 3.97-fold significantly increased with a risk difference of 3.97%. Among children diagnosed with DS, less than 6% were also diagnosed with an ASD. Among children diagnosed with an ASD, less than 5% were also diagnosed with DS. Children diagnosed with DS are apparently more susceptible to ASD diagnosis relative to the general population suggesting oxidative stress and transsulfuration pathway abnormalities are important susceptibility factors in ASD.
K E Y W O R D Sautism, down syndrome, glutathione, mercury, pervasive developmental disorder, sulfation 858 | GEIER Et al.
“…Alabdali et al [10], Biochemiker des Science College in Riad, untersuchten die Konzentration von 2 Schwermetallen, Blei und Quecksilber, in Erythrozyten von Kindern mit ASS sowie die Plasmaspiegel von Glutathion-S-Transferase (GST) und Vitamin E. Die Patienten mit ASS hatten deutlich erhöhte Quecksilber-und Bleiwerte sowie abgesenkte GST-und Vitamin-E-Werte. Blei wird z.…”
Section: Umweltgifte: Aluminium Blei Quecksilberunclassified
“…B. über Kohleheizung oder Feinstaub von Kohlekraftwerken, bleihaltige Autoabgase, Farbe und Haarfärbemitteln aufgenommen [9]. Die Autoren [10] sehen darin einen deutlichen Hinweis, dass Schwermetallablagerungen und möglicherweise Schwierigkeiten mit der körpereigenen Ent-giftung eine wichtige Rolle in der Ätiologie von ASS spielen.…”
Section: Umweltgifte: Aluminium Blei Quecksilberunclassified
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.